Chugai broadens label for Hemlibra in Japan

Tokyo-based Chugai Pharmaceutical (TYO: 4519) has won Japanese approval for additional dosing options for Hemlibra (emicizumab), a coagulation factor VIII substitute.

The therapy may be administered once weekly, every two weeks, or every four weeks, for routine prophylactic treatment for certain people with hemophilia A.

Chugai, which is majority-held by Swiss drugmaker Roche (ROG: SIX), is approved to market the therapy for people with hemophilia A with factor VIII inhibitors.